Quick Facts: Uses of Ansaid

• May provide relief for the symptoms of rheumatoid arthritis.
• May offer symptomatic management for osteoarthritis.
• Indicated for use in the symptomatic management of ankylosing spondylitis.
• May help address mild to moderate pain accompanied by inflammation.

---

Ansaid (flurbiprofen) is authorized for use in the management of specific conditions that involve pain and inflammation. This medication is primarily prescribed to help provide relief for the common signs and symptoms associated with chronic inflammatory joint conditions.

It is specifically indicated for the symptomatic management of rheumatoid arthritis and osteoarthritis that affect the joints. Use of the therapy may also be considered to help reduce the discomfort and stiffness related to ankylosing spondylitis, an inflammatory condition of the spine.

Furthermore, the drug is used to help address mild to moderate pain accompanied by inflammation, such as that associated with bursitis or tendinitis. Patients should consult their healthcare professional to understand the established therapeutic domains and to confirm if this treatment is appropriate for their individual needs.

Regulatory References

1. rheumatoid arthritis and osteoarthritis

Eligibility Profile: Official Regulatory Information

Ansaid (flurbiprofen) is generally allowed for use by adults for the symptomatic management of chronic joint conditions. The official eligibility profile is largely defined by absolute exclusions and restrictions related to its class as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Contraindicated Populations (Must Not Use)	Absolute Prohibitions (Selected)
Patients with known hypersensitivity to flurbiprofen, aspirin, or other NSAIDs.	History of recurrent peptic ulcers or GI bleeding.
Patients undergoing CABG surgery (peri-operative pain).	Severe hepatic, renal, or heart failure.
Patients in the last trimester of pregnancy (from 30 weeks gestation).	Hereditary metabolic disorders (tablet excipients).

Age and Condition-Based Restrictions

• Pediatric Use: Safety and efficacy have not been established; the medication is not recommended for use in children under 12 years of age.
• Geriatric Patients: Use requires caution due to a higher risk of serious gastrointestinal and renal adverse events; the lowest effective dose should be used.
• Impaired Organ Function: While contraindicated in severe hepatic or renal failure, patients with mild to moderate impairment may be eligible for use with monitoring.
• Pregnancy/Lactation: Use is avoided from 20 weeks gestation onward and is not recommended during breastfeeding.

Interactions with other medicines and products

The interaction profile of Ansaid (flurbiprofen) is officially documented by regulatory authorities, focusing on pharmacokinetic and pharmacodynamic interactions consistent with its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Formally Documented Restrictions

Restriction Category	Interacting Agents or Condition
Contraindicated Use	Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Not Generally Recommended	Co-administration with other NSAIDs (including COX-2 inhibitors) or analgesic/anti-inflammatory doses of Aspirin.

Pharmacodynamic and Exposure-Altering Interactions

Flurbiprofen may interact with several drug classes, potentially leading to specific outcomes documented in regulatory labels:

• Anticoagulants and Anti-platelet Agents: Co-administration results in a synergistic effect on bleeding, increasing the risk of serious gastrointestinal bleeding.
• Antihypertensives and Diuretics: Flurbiprofen may diminish the antihypertensive effect of ACE inhibitors, ARBs, and beta-blockers, and reduce the diuretic, natriuretic, and kaliuretic effects of diuretics.
• Lithium and Methotrexate: Flurbiprofen can decrease the renal clearance of Lithium, leading to elevated plasma concentrations, and may also increase methotrexate levels.
• Corticosteroids and SSRIs/SNRIs: Use with these agents increases the risk of gastrointestinal ulceration or bleeding.

Metabolic and Substance Interactions

Flurbiprofen's metabolism via the CYP2C9 enzyme means that CYP2C9 poor metabolizers may experience reduced clearance and abnormally high plasma levels. Additionally, official warnings note that concomitant ingestion of Alcohol increases the risk of gastric irritation and gastrointestinal mucosal bleeding.

Flurbiprofen (Ansaid) functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme family, specifically targeting both the inducible COX-2 and the constitutive COX-1 isoforms. The molecule binds reversibly and competitively to these enzymes, preventing the conversion of Arachidonic Acid into various prostanoids. This single molecular intervention results in the modulation of three separate physiological systems.

---

Modulating Prostaglandin Synthesis and Nociceptive Signaling

The primary action involves interrupting the biochemical cascade that produces Prostaglandin E2 ( PGE2), a crucial chemical messenger that sensitizes peripheral nociceptors (pain receptors). The resulting reduction in PGE2 prevents this excessive sensitization, producing a physiological outcome characterized by reduced nociceptive signaling.

---

Regulating Vascular and Thermoregulatory Responses

The suppression of PGE2 concentration systemically also modulates localized vascular tone and tissue response, which involves a reduction in vascular permeability, resulting in a physiological outcome characterized by reduced inflammation-related tissue changes. Concurrently, reduced PGE2 in the hypothalamus modifies the central temperature control set-point, resulting in a physiological outcome characterized by normalized thermoregulation.

How to Use Ansaid

The usage of Flurbiprofen, the active ingredient in Ansaid, is determined by its dosage form and the route of administration. The drug is used either orally as a tablet for systemic therapy, oromucosally as a lozenge for local relief, or topically as an ophthalmic solution for procedures involving the eye.

---

Official Dosing and Administration Patterns

The fundamental principle guiding the use of systemic Flurbiprofen is the administration of the lowest effective dosage for the shortest duration consistent with the treatment goals.

Usage Pattern	Oral Tablet (Systemic)	Lozenge (Local)
Typical Daily Dose Range	200 mg to 300 mg total, in divided doses	One 8.75 mg lozenge per dose
Maximum Daily Dose	300 mg	5 lozenges (43.75 mg)
Frequency	Administered two, three, or four times daily	One lozenge every 3 to 6 hours as needed
Intake Context	Recommended to be taken with or after food	Should be slowly dissolved in the mouth

Oral tablets are prescribed to be swallowed whole and must not be broken, cut, or chewed. The dose and frequency are typically adjusted to suit individual requirements after observing the response to initial therapy.

---

Population-Specific Usage Principles

Official labeling addresses usage in specific patient groups. For older adults and patients with renal impairment, dosing should be managed with caution, generally prioritizing the lowest effective dose. The safety and effectiveness of the oral tablet formulation have not been established for use in the pediatric population.

Research evidence / Overview of Studies for Ansaid (Flurbiprofen)

Evidence for Use in Inflammatory Joint Conditions (Rheumatoid Arthritis and Osteoarthritis)

Research related to flurbiprofen in rheumatoid arthritis (RA) and osteoarthritis (OA) symptoms includes short-term Randomized Controlled Trials (RCTs). These studies explored how symptoms change over time in adult patients with active disease. Researchers monitored outcomes related to physical discomfort and daily functioning, such as patient-reported scores for pain intensity, the duration of morning stiffness, and functional ability.

Studies report how symptoms evolved in the observed populations, and findings describe patterns of measured symptomatic outcomes over defined time intervals, typically lasting a few weeks up to three months. What remains uncertain is the long-term characterization of sustained functional outcomes. There is limited information for long-term outcomes specific to flurbiprofen beyond one year, and comparative evidence is lacking against certain other therapeutic approaches.

---

Evidence for Use in Ankylosing Spondylitis and Acute Pain

Flurbiprofen was evaluated in controlled clinical trials for use in ankylosing spondylitis, focusing on measures of spinal stiffness and pain relief. Research describes symptom patterns measured during short-term study periods. For general mild to moderate inflammatory pain, such as in tendinitis or bursitis, studies explored its use in acute pain models, measuring the onset of symptom change and the magnitude of change in pain scores over a few hours or days.

Evidence for Localized Relief of Sore Throat

The lozenge formulation of flurbiprofen was studied for localized symptomatic relief in acute sore throat using well-structured Randomized, Double-Blind, Placebo-Controlled Trials. Research examined specific endpoints like sore throat pain intensity and difficulty swallowing. Studies monitored physiological changes in the immediate post-dose period. Research is highly focused on acute relief and provides limited information regarding any long-term effects or recurrence patterns.

Gaps in Research and Areas of Uncertainty

Follow-up durations were limited in many core trials for chronic conditions. The evidence base for the stated indications shows that research is ongoing and that continued surveillance and long-term data collection may be useful to provide context but not individual predictions.

Key Studies & References

1. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial (Study assessing acute relief outcomes)
2. Flurbiprofen Geiser - EMEA-H-A-29(4)-1487 - Annex I-II-III (Regulatory assessment for lozenge formulation)

Common questions about Ansaid (FAQ)

Q: How quickly does Ansaid usually start to work for pain relief?

A: Studies and official information indicate that the active ingredient, flurbiprofen, is rapidly absorbed by the body. Peak levels in the bloodstream are typically measured about 2 hours after an oral dose. In research examining its use for acute pain, symptom changes are monitored soon after the medicine is taken.

Q: Does Ansaid have a risk of stomach irritation or bleeding?

A: Regulatory documents state that all medicines in this class (NSAIDs) carry a documented risk of serious gastrointestinal problems, including bleeding, ulceration, and perforation of the stomach or intestines. This serious risk may occur without warning symptoms. Regulatory warnings emphasize the need to use this medicine according to prescribed guidance.

Q: Is Ansaid generally safe for older adults (geriatric patients)?

A: Official labeling notes that use in older adults requires caution. This population is documented to be at significantly greater risk for serious side effects, particularly those affecting the stomach and intestines. Dosing principles for older adults often prioritize the lowest effective amount for the shortest time, as outlined in official labeling.

Q: Can Ansaid affect liver or kidney function?

A: Official warnings state that long-term use of NSAIDs may cause or worsen existing kidney problems. The drug is officially contraindicated (must not be used) in cases of severe liver or kidney failure. Individuals with mild-to-moderate impairment may still be eligible for use, but monitoring may be required.

Q: What is the information on Ansaid use for women who are planning a pregnancy?

A: According to the official product information, flurbiprofen is generally not recommended for women who are actively trying to conceive or who are being investigated for infertility. This is because medicines in the NSAID class may be associated with affecting female fertility.

Q: Does Ansaid only treat symptoms or does it stop disease progression?

A: Flurbiprofen is classified and used as a medicine to relieve the signs and symptoms of conditions like arthritis. Regulatory information indicates the drug is a symptomatic treatment and is not documented to stop the underlying disease from getting worse.

Q: Can Ansaid be taken for pain that is not related to arthritis?

A: Authoritative sources note that the active ingredient, flurbiprofen, may be used for various non-arthritis conditions to relieve pain. These uses may include relief of dental pain, muscle aches, or other acute inflammatory pain.

Q: Can Ansaid affect blood pressure?

A: Official documents state that NSAIDs, including flurbiprofen, may lead to the onset of new high blood pressure or cause pre-existing high blood pressure to worsen. This effect may contribute to the increased risk of cardiovascular events.

Q: Why is Ansaid sometimes prescribed for painful menstrual periods?

A: Regulatory-cited sources list relief of menstrual cramps (known clinically as primary dysmenorrhea) as one of the conditions for which flurbiprofen may be used. Its mechanism of reducing prostaglandins helps in the management of pain associated with menstruation.

Q: Is Ansaid associated with an increased risk of stroke?

A: Official warnings state that NSAIDs, including Ansaid, cause an increased risk of serious cardiovascular thrombotic events, including heart attack and stroke. This risk may occur early in treatment, and it may increase if the medicine is taken for a longer duration.

Q: Can Ansaid interfere with the effects of diuretics ('water pills')?

A: Yes, regulatory documentation states that flurbiprofen can reduce the natriuretic effect of diuretics, such as furosemide and thiazides. This may result in a reduction in the expected effects of the diuretic.

Q: Does Ansaid contain a steroid?

A: No. Ansaid is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The term 'nonsteroidal' in the classification indicates that it is not a steroid-based medicine.

Q: What is known about the use of Ansaid in children?

A: The safety and effectiveness of the oral tablet formulation of Ansaid have not been established for use in the pediatric population. Therefore, the medicine is generally not indicated or recommended for use in children under 12 years of age.

Q: Can Ansaid cause drowsiness or affect concentration?

A: Yes. Adverse reactions listed in regulatory documents include central nervous system effects such as drowsiness, dizziness, and fatigue. Some official reports also mention the possibility of difficulty concentrating.

Q: Can Ansaid cause visual disturbances or ringing in the ears (tinnitus)?

A: Official documents list both ringing in the ears (tinnitus) and changes in vision as adverse reactions that have been reported with the use of flurbiprofen.

Q: Are there any reported psychiatric side effects linked to Ansaid?

A: Side effects listed in regulatory documents include central nervous system and psychiatric effects. These may include feelings of nervousness, anxiety, insomnia, depression, and confusion.

Q: Is Ansaid a narcotic or does it have a risk of dependence?

A: No. Ansaid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic, and there is no documented risk of dependence associated with its use.

Q: Has Ansaid been studied for use in treating gout?

A: Some authoritative sources note that flurbiprofen has been associated with the treatment of symptoms related to acute gout attacks, although this may not be a primary approved indication.

Q: How does Ansaid compare to Naproxen (another NSAID) in terms of general use?

A: Flurbiprofen and Naproxen both belong to the same Nonsteroidal Anti-inflammatory Drug (NSAID) class. Both medicines function similarly by inhibiting the cyclooxygenase (COX) enzyme to manage pain and inflammation.

Q: Are there specific symptoms that indicate I should stop taking Ansaid?

A: Patients are advised by regulatory documents to seek medical attention immediately and stop taking the drug if they experience symptoms related to serious side effects. Examples include chest pain, difficulty breathing, sudden weakness, or signs of stomach bleeding (such as bloody or black/tarry stools).

Q: What types of allergic reactions are associated with Ansaid?

A: The drug is associated with a risk of serious allergic reactions, including hives, rash, itching, swelling of the face or throat, and difficulty breathing. There is also a risk of potentially life-threatening anaphylactoid reactions, as noted in official safety information.

Storage and Disposal of Ansaid (Flurbiprofen)

Ansaid tablets must be stored at Controlled Room Temperature (CRT), maintained between 20 C and 25 C (68 F and 77 F). The regulatory labeling permits temporary temperature excursions only up to 30 C.

Required Protection

The product must be protected from light and moisture to preserve its stability. To ensure safety, the medication must be kept out of the reach of children, as required by official pharmaceutical standards.

Disposal

There are no special requirements specified in the regulatory labeling for the disposal of Ansaid tablets. Unused or expired medication must be discarded according to local regulations for pharmaceutical waste.